
簡(jiǎn)要描述:HMN-214 173529-46-9HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.
產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 173529-46-9 |
|---|---|---|---|
| 分子式 | C22H20N2O5S | 純度 | 99% |
| 分子量 | 424.47 | 貨號(hào) | abs47028045 |
| 規(guī)格 | 5mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a potent PLK1 inhibitor | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
HMN-214 173529-46-9
| 產(chǎn)品描述 | |
| 描述 | HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
| 純度 | 99% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | HMN-214,HMN214,HMN 214,IVX214 |
| 可溶性/溶解性 | 10 mM in DMSO |
| 生物活性 | |
| 靶點(diǎn) | Polo-like Kinase (PLK) |
| In vitro(體外研究) | HMN-214 is a prodrug of HMN-176. HMN-176 shows potent activities against 22 human tumor cell lines, with a mean IC50s of 118 nM. HMN-176 (3-300 nM) inhibits luciferase expression driven by the MDR1 promoter in a dose dependent manner in HeLa cells. HMN-176 (30-3000 nM) also dose-dependently suppresses complex formation on the Y-box. HMN-214 (3.3 μM) enhances luciferase expression relative to vehicle control with the 1,4C-1,4Bis polymer (11-fold) and PEI (37-fold) in PC3-PSMA cells. HMN-214 (≥ 3.3 μM) significantly reduces cell proliferation, causes considerable changes in cell morphology in MB49 cells. |
| In vivo(體內(nèi)研究) | HMN-214 (33 mg/kg, p.o.) converts to HMN-176 in rats. HMN-214 has no effect on the conduction velocity and the amplitude of action potentials in the aciatic and tibial nerves. HMN-214 (20 mg/kg, p.o.) exhibits antitumor activity in mice. HMN-214 (10, 20 mg/kg, p.o.) decreases MDR1 mRNA expression in nude mice bearing KB- and KB-A.1.-derived tumors. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerCell cycleCell division Cell CycleCell DivisionSpindle Cell CycleKinases/PhosphatasesOther EpigeneticsCell cycleKinases/PhosphatasesOther NeuroscienceProcesses Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
